AI stock analysis · Diagnostics & Research · Last analyzed Aug 18, 2026
Compass Score
4.0/5
Call
Buy
Price
$585.51
AI Target
$631.42 +7.8%
AI Analyst Summary
Thermo Fisher Scientific is a dominant life sciences platform benefiting from durable demand in bioproduction, analytical instruments, and clinical research services, with revenue growing 10.5% YoY and a forward P/E of 21.3x that implies meaningful re-rating potential as earnings expand. Management's consistent EPS outperformance across all four recent quarters and near-unanimous analyst Buy consensus signal a high-quality compounder with reliable execution. The primary risk is continued softness in biopharma customer spending and destocking cycles, which could constrain near-term top-line acceleration.
Catalysts
Recovery in biopharma and biotech end-market capex spending, which could accelerate instrument order intake and bioproduction revenues in H2 2025
Expansion of the pharma services segment driven by CDMO outsourcing tailwinds and new large-molecule drug development mandates
Continued EPS beat cadence in upcoming quarterly earnings, which could prompt upward consensus estimate revisions and price target upgrades from the 6 Hold-rated analysts
Risks
Prolonged biopharma destocking and budget conservatism among large pharma customers could suppress instrument and consumables demand, pressuring the 10.5% revenue growth rate
A stronger U.S. dollar represents a meaningful FX headwind given TMO's significant international revenue exposure across Europe and Asia-Pacific
At a trailing P/E of 31.6x, any guidance cut or macro deterioration could trigger a de-rating, with limited valuation cushion at current price levels
Fundamentals
PeTrailing P/E 31.6x / Forward P/E 21.3x · 3.0/5
Trailing P/E of 31.6x is modestly above the healthcare sector median, but the forward P/E of 21.3x reflects meaningful earnings expansion ahead. Valuation is fair for a high-quality compounder but not a bargain.
PegPEG 1.92 · 3.0/5
PEG of 1.92 sits in neutral territory — not cheap, not stretched. Reflects a business growing at a solid but not explosive pace relative to its valuation multiple.
Analyst RatingStrong Buy consensus (1.5) · 5.0/5
22 Buy ratings vs. 6 Hold and 0 Sell out of 26 analysts. Consensus sits at 1.5, mapping to a top-tier bullish signal with broad coverage and no dissenting Sell votes.
Mid-single to low-double-digit growth is respectable for a company of this scale, but not accelerating. Revenue growth slightly outpaces earnings growth, suggesting some margin pressure. Trend is positive but not exceptional.
A perfect 4-for-4 EPS beat rate over the most recent four quarters demonstrates consistent execution. Only 4 quarters of data limits the score to a 4 rather than a 5, but the trend is clearly constructive.
Flawless near-term EPS beat record and near-unanimous bullish analyst sentiment reflect high confidence in management's ability to deliver. Capital allocation has historically been disciplined with strategic M&A and share buybacks supporting per-share growth.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.